share_log

Benchmark Reiterates Buy on Biofrontera, Maintains $18 Price Target

Benzinga ·  Aug 31, 2023 08:42

Benchmark analyst Bruce Jackson reiterates Biofrontera (NASDAQ:BFRI) with a Buy and maintains $18 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment